Digital Asset DirectOrganicell Regenerative Medicine, Inc.
Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/
November 22, 2022 11:33 AM Eastern Standard Time
Video
News ReleaseAiViva BioPharma
AiViva BioPharma is a clinical-stage biotech company developing innovative and transformative treatments and products to address unmet medical needs for a wide array of diseases. AiViva has created a diverse product pipeline powered by its proprietary technology and new and innovative treatments. It has built a strong patent position to protect products to be commercialized for worldwide sales from its diverse product pipeline for ophthalmology, dermatology, urology, and oncology. The company has a veteran management team with a combined 300 years of experience at its helm. The California-based company has raised $30+ million in capital, including $10 million in 2022, and is buzzing with action and optimism. It boasts a robust clinical pipeline focused on wet, age-related macular degeneration (wAMD), prostate disorders, and nonmelanoma skin cancer. How AiViva’s Proprietary JEL™ Technology Works AiViva’s proprietary JEL™ technology is aimed at prolonging the therapeutic effects of drugs and enhancing their benefits. A key outcome of this strategy is a reduction in treatment frequency and systemic toxicity, which relieves patients of multiple visits to the doctor while gaining improved outcomes. AiViva’s JEL™ technology allows for the placement of the drug directly at the site of disease, where it forms a drug-infused mass or drug depot for prolonged drug release. Its delivery medium is a liquid at room temperature. When it’s injected into the diseased tissue at a warmer body temperature, it quickly hardens into a gelatin-like mass. This drug-infused gelatin serves as a storehouse, releasing the drug for release over time. The company says its JEL™ delivery platform offers customizable drug release and treatment duration for different therapies, making it a versatile drug delivery platform for the treatment of many major diseases, including solid tumors and wAMD. AiViva’s current focus is wAMD, and it’s set to begin clinical trials using its AIV007 compound combined with JEL™ in 2023. wAMD is a chronic eye disorder that causes blurred vision or a blind spot caused by abnormal blood vessels that leak fluid or blood into the macula — the area of the eye that provides the sharp, central vision needed for reading, driving and seeing fine detail — and scars it over time. Current treatments for this disorder only address the abnormal blood vessel growth (neovascularization) — not the formation of scar tissue or fibrosis. Leaving the scar tissue untreated could result in irreversible vision loss. There is no cure for wAMD. AiViva says its novel compound AIV007 embedded in JEL™ offers superior outcomes for wAMD because it targets neovascularization and addresses cell proliferation and fibrosis (scarring), improving impaired vision or preventing vision loss. In addition, AIV007 in JEL™ delivers localized and precise treatment, unlike most medicines that spread throughout the body randomly. AiViva’s technology only requires placing a tiny amount of drug at the disease site and ensures the drug remain there for a long treatment effect. This precision medicine would achieve good therapy outcome without annoying side effects, reduce the number of doctor’s visits. A Technology Backed By Patents That Could Be Applicable In Multiple Disease Treatments Applying the principles of its JEL™ technology, AiViva is targeting other major diseases that involve neovascularization, abnormal tissue growth and fibrosis, including benign prostate hyperplasia (enlargement of men’s prostates), low-grade prostate cancers and skin disorders. AiViva has ongoing clinical trials in skin cancer and keloid scarring for the compound AIV001. It has wAMD lined up as its next candidate for clinical trials. The indications targeted by AiViva represent a combined multi billion revenue potential, according to the company. The technology is protected beyond 2040 by patent applications in major markets, including Europe, Japan, China and the U.S. The company reports allocating almost 80% of its capital to research and development in the past years, through which it has been able to bring several projects through Food and Drug Administration’s (FDA) Investigational New Drug Applications (INDs). A Seasoned Management Team AiViva’s website highlights a management team of highly experienced industry experts with successful track records in drug development and commercialization. Its board members have been described as having led successful initial public offerings (IPOs) on the New York Stock Exchange (NYSE) and the Nasdaq Stock exchange. Here’s a look at some of them: Co-Founder and CEO Diane Tang-Liu held several senior executive positions at Allergan Plc. (NYSE: AGN), leading research and development (R&D) programs for over 30 years. Director Johnson Lau is CEO of Athenex Inc. (NASDAQ: ATNX) and was chair of the $75 million Athenex IPO in 2017. Johnson was previously CEO of Ribapharm Inc. (NYSE: RNA), which launched a $299 million IPO on the New York Stock Exchange in 2002 — the second-largest biotech IPO in history at the time. Director Larry Hsu was co-founder, president and CEO of Impax Laboratories Inc. (NASDAQ: IPXL), a company that had a market cap of about $3 billion at the time of his retirement. Director Jinn Wu was Dr. Jinn Wu is the Founder and President of XenoBiotic Laboratories, Inc. (XBL) in Plainsboro, New Jersey, and XBL-China in Nanjing, China. WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), acquired XenoBiotic Laboratories, Inc. With an impressive team leading the charge at AiViva, the company is optimistic about its ability to raise capital and believes its investors could reap high returns on their investment if the past experience of its collective leadership in leading IPOs is anything to go by. To learn more about AiViva visit the company website. To invest in AiViva go here. AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The preceding post was written and/or published as a collaboration between Benzingaâs in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuerâs securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. Contact Details Michael office@aiviva.com Company Website https://aiviva.com/
November 22, 2022 08:00 AM Eastern Standard Time
News ReleaseYourUpdateTV
There is a long history of stigma surrounding obesity and weight loss medications. When diet and exercise don’t lead to effective weight loss, sometimes it’s our biology that’s holding us back. Recently, Dr. Rekha Kumar, Head of Medical Affairs at Found, conducted a satellite media tour to talk about personalized weight loss and its benefits. A video accompanying this announcement is available at: https://youtu.be/qUhnxU91uPY Science shows that our biology can dictate up to 70% of weight gain, loss, and maintenance — yet the weight loss industry still reduces a person’s success to diet, exercise, and willpower. A variety of biological factors like genetics, hormones, metabolic rate and others contribute to our body’s “setpoint weight,” which is a certain weight that your body favors that is usually at the higher end of the scale. Your body wants to stay at this weight and fights hard to keep you there, and will even lower your metabolism or amp up your hunger signals to get back to your set point weight. Blaming obesity on a lack of willpower can take a psychological toll, causing people to feel shame, guilt, frustration or judgment, and fail to address biology as the core issue. Why Prescription Medication for Weight Loss? Obesity is a complicated disease that affects 40% of the US population, and it takes a personalized approach to each individual’s biology to treat it. Prescription medication can help people lose weight by fighting against their biology. Some medications work by suppressing appetite, and others work by curbing cravings. Weight loss medications have different mechanisms, and a doctor will have to evaluate if you're a good candidate for any of them. Not every medication is right for every person, and it’s common that if one doesn't work, a clinician might recommend trying a different medication. Historically, clinical care pathways for obesity management have only been available for patients at premiere academic medical centers, and typically have long wait lists. The Found’s program addresses a clear gap in access to weight care: Today, more than 40% of Americans have obesity, and yet only 1% of physicians specialize in obesity medicine. The medications Found offers are supported by clinical evidence to be highly effective and safe for helping aid with weight loss. Found has seen that members receiving medication plus behavior change support on the Found program have lost at least 13% more weight, and in some cases up to 229% more weight, than people receiving the same medication in clinical studies. Found is the largest online weight care clinic in the country, helping more than 160,000 Americans with their weight loss journey to-date. Found offers 13 different medications that can be combined to create more than 60 different possible treatment paths, available through their Prescription Program, each uniquely paired to address a person's biological and medical history. Found’s wide toolkit of medications fundamentally helps to serve a broader audience than others in the space. The Practice of Responsible Prescribing Found-affiliated providers are trained in the Found treatment protocol, which looks at various factors to determine the medication that will be safest and most effective for a member’s individual needs.Found-affiliated practitioners prescribe both FDA-approved branded anti-obesity medications as well as off-label generic combinations when determined safe by the treating clinician. The medications prescribed are the same medications that are offered in premiere academic medical centers.Treatment through the Found platform expands access to obesity treatment by bypassing long waitlists for appointments and copays for visits at in-person clinics. Found-affiliated medical providers are expected to always provide treatment and care that is in the best interest of their patients. For more information on Found’s weight care program, please visit joinfound.com Bio for Dr. Rekha Kumar, M.D., M.S. Dr. Rekha Kumar is recognized as an international leader in the field of Obesity Medicine. She is Head of Medical Affairs at weight care platform Found, as well as a practicing endocrinologist at an academic medical center in New York City. She also served as the former medical director of the American Board of Obesity Medicine. Dr. Kumar has lectured internationally on the topic of the medical assessment and treatment of obesity. She has published several papers and textbook chapters in her field and serves as an Associate Editor of the journal Obesity. She is frequently quoted in the media on topics ranging from the diabetes epidemic in the United States to discussing fad diets, exercise trends, and the complications of Covid-19 in patients with obesity. Dr. Kumar’s areas of expertise include the clinical assessment of patients with obesity and metabolic syndrome, the effect of obesity on reproductive health and fertility, and thyroid disease. Dr. Kumar completed her undergraduate studies at Duke University then received her master’s degree in Physiology from Georgetown University. She continued on to receive her M.D. from New York Medical College and completed her residency training in Internal Medicine at the New York Presbyterian Hospital/Weill-Cornell Medical College. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the Weill-Cornell Medical College/New York Presbyterian Hospital and the Memorial Sloan Kettering Cancer Center. Dr. Kumar has traveled abroad to India, China, and Tanzania to understand the scope of metabolic disease globally. She serves on the board of advisors of the Duke Global Health Institute. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
November 22, 2022 07:00 AM Eastern Standard Time
Video
News ReleaseYourUpdateTV
Click to view video featuring Jean Chatzky: https://youtu.be/-nGhkeAo0G8 Are You Saving Enough for Future Healthcare Expenses? New research from Synchrony’s “Lifetime of Healthcare Costs” Study reveals the average individual insured Americans cost of out-of-pocket healthcare costs from age 18 to the average life expectancy of age 79. Many of us save for significant costs, such as a home mortgage, a new car, or college tuitions. But when it comes to our own health – which should be the most important thing to take care of – we don’t take under consideration how much we pay annually outside of what is covered by insurance. Jean Chatzky conducted a nationwide media tour in partnership with Synchrony to provide real world advice and steps to help bridge the clear gap between people’s perceptions and the reality of the costs of healthcare today. During radio and TV interviews across the country, Jean Chatzky discussed: What the recent survey said about the cost of healthcare Surprising results from the survey Why it is so important for Americans to understand these out-of-pocket healthcare costs Valuable resources people can use to help manage these costs For more information visit: carecredit.com/lifetime-study/ Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
November 21, 2022 02:00 PM Eastern Standard Time
Video
News ReleaseThe Chicago School of Professional Psychology
Emphasizing that community service is “in the DNA” of The Chicago School of Professional Psychology, a dozen members of its Board of Trustees last week participated in an outreach project to benefit unhoused people in Los Angeles. About 600 kits, including blankets and personal care items, were collected, boxed and hand-delivered to residents of Los Angeles’ Skid Row, according to Dr. Nadia Rojas Jones, the faculty member who has organized the annual effort with students from the school’s three Southern California campuses for the past seven years. “We are here to show our support of faculty and students in their efforts to help underserved populations, whether it’s those without permanent shelter or in communities of color or people with low income,” said Terrence Joe Layng, Ph.D., Chair of the Board of Trustees. “The commitment to community service is what differentiates The Chicago School-- our students and faculty are deeply involved in the communities they serve,” said Trustee Victoria Dolan, former CFO of Revlon. Every year, The Chicago School’s students provide 1.2 million volunteer service hours in 600 organizations across the United States, according to Dr. Michele Nealon, Psy.D. “There are nearly 70,000 unhoused individuals in Los Angeles County today, a four percent increase from two years ago,” she said. “We know that many of them have mental health issues that are going undiagnosed and untreated.” The Chicago School of Professional Psychology, a non-profit higher education institution headquartered in Los Angeles, serves 6,000 students on seven U.S. campuses (including online). Two-thirds of the student body identifies as people of color. # About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu
November 21, 2022 07:00 AM Pacific Standard Time
Digital Asset DirectDestiny Pharma PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
November 21, 2022 09:19 AM Eastern Standard Time
Video
Digital Asset DirectNetScientific PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
November 21, 2022 09:06 AM Eastern Standard Time
Video
News ReleaseKnow Labs, Inc.
A U.S.-based medical device company recently completed its successful uplisting to the New York Stock Exchange (NYSE) American exchange. Know Labs Inc. (NYSEAMERICAN: KNW) raised over $8 million from its public offering of common stock. Know Labs announced listing approval to NYSE American in mid-September as an exciting opportunity to join the exchange for growing companies and closed its public offering within four days. It increased the public offering of stock by 15% from the original filing as part of its over-allotment option. Though it initially announced trading a public offering of 3.6 million at $2 a share, it ended up trading 4.14 million. This increase means Know Labs closed with over $1 million more than anticipated — raising $8.28 million before underwriting discounts, commissions and other expenses. This high trading activity is not unfamiliar to Know Labs. The company’s recent high trading volume saw it added to the OTCQB Venture Market’s Top 10 Most Active list. Bringing Its Cutting-Edge Tech To Emerging Companies Exchange Know Labs was uplisted to the NYSE American under the symbol KNW, changing from its previous symbol KNWN as it will no longer be traded on the over-the-counter (OTC) market. As an emerging company looking for cutting-edge medical tech solutions, Know Labs will use the money raised from the stock sales for further research and development as well as sales and marketing, working capital, capital investments and various administrative expenses. Know Labs is committed to making a difference in the lives of millions of people around the world by developing convenient affordable non-invasive medical diagnostics solutions. Know Labs has been focused on the research and development of proprietary spectroscopic technologies using the electromagnetic spectrum to accurately identify and measure a wide range of organic and inorganic materials, molecules, and compositions of matter.he company refers to it as Bio-RFID™ (body radio frequency identification). Know Labs has been working on applying Bio-RFID to monitor blood glucose levels, a fast-growing multi-billion market. The Company claims to have 89 patents granted, pending or in-filling process, which could position it as the top worldwide IP holder in non-invasive blood glucose monitoring.Other companies innovating with technology for diabetic patients include Novo Nordisk A/S (NYSE: NVO) and Movano Inc. (NASDAQ: MOVE). Know Labs also claims Bio-RFID has more than 100 uses beyond glucose monitoring. These include the identification of blood levels of oxygen, alcohol and metabolized drugs. Its versatile technology platform can be integrated into various wearable, mobile or bench-top form factors, meaning the company may produce low-cost, noninvasive diagnostic technologies with a broad spectrum of applications and uses across industries. To learn more about Know Labs, visit its website. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Know Labs info@visualant.net Company Website http://www.knowlabs.co
November 21, 2022 08:00 AM Eastern Standard Time
Digital Asset DirectPoolbeg Pharma PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
November 21, 2022 06:35 AM Eastern Standard Time
Video
Contact Us
Pricing
About us
Features
News Hub
Terms of Use
Privacy Policy